Synthesis, antimycobacterial and antifungal evaluation of 3-arylaminopyrazine-2,5-dicarbonitriles

Archiv der Pharmazie

Volumn 341, Issue 1, 2008, Pages 61-65

  Palek, Lukáš ^a   Dvořák, Jaroslav ^a   Svobodová, Michaela ^b   Buchta, Vladimír ^b   Jampílek, Josef ^c   Doležal, Martin ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c Zentiva Prague   (Czech Republic)

Author keywords

Antibacterial agents; Antimycotic activity; Antitubercular activity; Pyrazinamide analogues

Indexed keywords

3 (2 CYANO 4 NITROPHENYLAMINO)PYRAZINE 2,5 DICARBONITRILE; 3 (2 HYDROXY 4 NITROPHENYLAMINO)PYRAZINE 2,5 DICARBONITRILE; 3 (2 MERCAPTOPHENYLAMINO)PYRAZINE 2,5 DICARBONITRILE; 3 (3 CHLOROPHENYLAMINO)PYRAZINE 2,5 DICARBONITRILE; 3 (3,5 DIBROMO 4 HYDROXYPHENYLAMINO)PYRAZINE 2,5 DICARBONITRILE; 3 (4 FLUOROPHENYLAMINO)PYRAZINE 2,5 DICARBONITRILE; 3 [[2 (TRIFLUOROMETHYL)PHENYL]AMINO]PYRAZINE 2,5 DICARBONITRILE; 3 [[3 (TRIFLUOROMETHYL)PHENYL]AMINO]PYRAZINE 2,5 DICARBONITRILE; 3 ARYLAMINOPYRAZINE 2,5 DICARBONITRILE DERIVATIVE; 6 CHLOROPYRAZINE 2,5 DICARBONITRILE; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; FLUCONAZOLE; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGUS; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SUBSTITUTION REACTION;

ABSIDIA; ANTIFUNGAL AGENTS; ANTITUBERCULAR AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; NITRILES; PYRAZINAMIDE; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRICHOSPORON;

EID: 38949196696     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700119     Document Type: Article

References (16)

1. XDR-ndash;TB UPDATE/E5> 2006: http://www.who.int/tb/xdr/ dir_stb_message_25sep06/en/index.html (12. June 2007).
2. EU determined to eradicate TB: http://cordis.europa.eu/fetch?CALLER= EN_NEWS&ACTION=D&SESSION=&RCN=21787 (12. October 2006).
3. Treatment of tuberculosis: http://www.cdc.gov/MMWR/preview/mmwrhtml/ rr5211a1.htm (12. June 2007).
4. M. Doležal, M. Miletín, J. Kuneš, K. Králová, Molecules 2002, 7, 363-373.
5. M. Doležal, J. Jampílek, Z. Osicka, J. Kuneš, V. Buchta, P. Víchová, Farmaco 2003, 58, 1105-1111.
6. M. A. Hassan, S. E. Zayed, W. N. El-Gaziri, S. Metwally, Arch. Pharm. 1991, 324, 185-187.
7. M. H. Cynamon, R. J. Speirs, J. T. Welch, Antimicrob. Agents Chemother. 1998, 42, 462-463.
8. K. Dlabal, K. Palat, A. Lycka, Z. Odlerova, Collect. Czech. Chem. Commun. 1990, 55, 2493-2501.
9. J. Jampílek, M. Doležal, J. Kuneš, D. Šatínský, I. Raich, Curr. Org. Chem. 2005, 9, 49-60.
10. J. Jampílek, L. Palek, M. Doležal, ECSOC-10, 2006, November 1-30 http://www.usc.es/congresos/ecsoc/10/GOS/a019/index. htm.
11. F. E. Norrington, R. M. Hyde, S. G. Williams, R. J. Wootton, Med. Chem. 1975, 18, 604-607.
12. http://www.taacf.org/about-TAACF.htm (12. June 2007).
13. L. Collins, S. G. Franzblau, Antimicrob. Agents. Chemother. 1997, 41, 1004-1009.
14. W. McDermott, R. Tompsett, Am. Rev. Tuberc. 1954, 70, 748-754.
15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast: Approved Standard, NCCLS document, M27-A; NCCLS: Villanova, PA, USA, 1997.
16. S. Kushner, H. Dalalian, J. L. Sanjurjo, F. L. Bach Jr., et al., J. Am. Chem. Soc. 1952, 74, 3617-3621.